pegylated liposomal dexamethasone

Pegylated liposomal dexamethasone is a formulation of dexamethasone in which the drug is encapsulated within long-circulating, cholesterol-stabilized, poly(ethylene glycol)-coated (PEGylated) liposomes, designed for intravenous administration. The formulation uses liposomes of approximately 100 nm diameter, which enables prolonged circulation time and targeted delivery to pathological sites such as the bone marrow and inflamed tissues. **Dexamethasone** is a potent synthetic glucocorticoid that exerts anti-inflammatory, immunosuppressive, and antitumor effects, primarily through glucocorticoid receptor-mediated gene regulation leading to cellular apoptosis and inhibition of pro-inflammatory cytokines (such as IL-6, TNF-α), and reduction of immune cell activity. The **pegylated liposomal delivery** aims to enhance efficacy by concentrating the drug in target tissues while reducing systemic toxicity and off-target effects. Preclinical and early clinical studies have focused on the treatment of multiple myeloma, prostate cancer bone metastases, and rheumatoid arthritis, with an improved safety profile and pharmacokinetics compared to free dexamethasone[1][3][5].

Other names

pegylated liposomal dexamethasoneDex-PLPEG-liposomal dexamethasone phosphate